Radiofrequenzablation in der Behandlung des Barrett-Ösophagus

Zusammenfassung

Die Radiofrequenzablation (RFA) hat sich in den letzten Jahren als wertvolles therapeutisches Verfahren in der Behandlung des neoplastischen Barrett-Ösophagus (BÖ) etablieren können. Bei ausgewählten Patienten wird die RFA dabei als alleiniges Verfahren eingesetzt, wenn eine frühe Neoplasie ohne eine endoskopisch detektierbare fokale Läsion histologisch nachgewiesen wurde. In den meisten Fällen erfolgt sie jedoch additiv nach durchgeführter endoskopischer Resektion (ER) einer fokalen Läsion zur Ablation residualer, nicht neoplastischer Barrettschleimhaut. Klinische Studien konnten zeigen, dass die RFA ein effektives und sicheres Verfahren mit niedriger Komplikationsrate darstellt und in der Regel zu einer kompletten Eradikation des BÖ mit langfristigem Therapieerfolg führt.

Abstract

In recent years radiofrequency ablation using the BÂRRX-system in the treatment of Barrett’s esophagus has become well established. In combination with prior endoscopic resection radiofrequency ablation is a valuable therapeutic technique in selected patients with early Barrett’s neoplasia for the prevention of recurrences or metachronous neoplasia. Clinical trials demonstrate that radiofrequency ablation is safe and highly effective, has low complication rates, preserves the functional integrity of the esophagus, is easy to apply and shows generally lasting therapeutic success.

Schlüsselwörter

Barrett-Ösophagus - Barrett-Frühkarzinome - Radiofrequenzablation - endoskopische Resektion

Keywords

Barrett’s Esophagus - early Barrett’s Neoplasia - Radiofrequency ablation - endoscopic resection

• Literatur

• 1 Pech O, Behrens A, May A et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut 2008; 57: 1200-1206
• 2 Manner H, Pech O, Heldmann Y et al. Efficacy, safety and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol 2013; 11: 630-635
• 3 Pouw RE, Wirths K, Eisendrath P et al. Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett’s esophagus with early neoplasia. Clin Gastroenterol Hepatol 2010; 8: 23-29
• 4 Phoa KN, Pouw RE, Bisschops R et al. Radiofrequency ablation combined with endoscopic resection is highly effective for eradication of early Barrett’s neoplasia: final results of a large prospective european multicenter study. (EURO II). GIE 2013; 77 (Suppl. 05) AB137
• 5 Shaheen NJ, Sharma P, Overholt BF et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009; 22: 2277-2288
• 6 Bulsiewicz WJ, Kim HP, Dellon ES et al. Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrett’s esophagus. Clin Gastroenterol Hepatol 2013; 11: 636-642
• 7 Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; (epub ahead)
• 8 Wani S, Falk G, Post J et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology 2011; 141: 1179-1186
• 9 Hvid-Jensen F, Pedersen L, Drewes AM et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011; 365: 1375-1383
• 10 Curvers WL, ten Kate FJ, Krishnadath KK et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010; 7: 1523-1530
• 11 Sikkema M, Looman CW, Steyerberg EW et al. Predictors for neoplastic progression in patients with Barrett’s esophagus: a prospective cohort study. Am J Gastroenterol 2011; 106: 1231-1238
• 12 Hur C, Choi SE, Rubinstein JH et al. The cost effectiveness of radiofrequency ablation for Barrett’s esophagus. Gastroenterology 2012; 143: 567-575
• 13 Wani S, Falk G, Hall M et al. Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011; 9: 220-227
• 14 Desai TK, Krishnan K, Samala N et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut 2012; 61: 970-976
• 15 Fleischer DE, Overholt BF, Sharma VK et al. Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 2010; 10: 781-789
• 16 Choi YN, Willekens H, Coremans G et al. Short term side effects after radiofrequency ablation. Are we ready to ablate non-dsyplastic Barrett?. Gut 2011; 60 (Suppl. 03) A59
• 17 van Vilsteren FG, Phoa KN, Alvarez Herrero L et al. Circumferential ballon-based radiofrequency ablation of Barrett’s esophagus with dysplasia can be simplified, yet efficacy maintained, by omitting the cleaning phase. Clin Gastroenterol Hepatol 2013; 11: 491-498
• 18 van Vilsteren FG, Phoa KN, Alvarez Herrero L et al. A simplified regimen for focal radiofrequency ablation of Barrett’s mucosa: a randomized multicenter trial comparing two ablation regimes. Gastrointest Endosc 2013; 78: 30-38
• 19 van Vilsteren FG, Alvarez Herrero L, Pouw RE et al. Radiofrequency ablation and endoscopic resection in a single session for Barrett’s esophagus containing early neoplasia: a feasibility study. Endoscopy 2012; 44: 1096-1104
• 20 van Vilsteren FG, Alvarez Herrero L, Pouw RE et al. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett’s esophagus with early neoplasia: a prospective multicenter study. Endoscopy 2013; 45: 516-525
• 21 Shaheen NJ, Overholt BF, Sampliner RE et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology 2011; 141: 460-468
• 22 Gupta M, Iyer PG, Lutzke L et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US Multicenter Consortium. Gastroenterology 2013; 145: 79-86
• 23 Haidry RJ, Dunn JM, Butt MA et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett’s esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RF Registry. Gastroenterology 2013; 145: 87-95
• 24 Phoa KN, Pouw RE, van Vilsteren FG et al. Remission of Barrett’s esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 2013; 145: 96-104
• 25 Chung A, Bourke MJ, Hourigan LF et al. Complete Barrett’s excision by stepwise endoscopic resection in short-segment disease: long-term outcomes and predictors of stricture. Endoscopy 2011; 43: 1025-1032
• 26 Pouw RE, Seewald S, Gondrie JJ et al. Stepwise radical endoscopic resection for eradication of Barrett’s oesophagus with early neoplasia in a cohort of 169 patients. Gut 2010; 59: 1169-1177
• 27 van Vilsteren FG, Pouw RE, Seewald S et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia of early cancer: a multicentre randomised trial. Gut 2011; 60: 765-773
• 28 Shaheen NJ, Peery AF, Overholt BF et al. Biopsy depth after radiofrequency ablation of dysplastic Barrett’s esophagus. Gastrointest Endosc 2010; 72: 490-496
• 29 Odze RD, Lauwers GY. Histopathology of Barrett’s esophagus after ablation and endoscopic mucosal resection therapy. Endoscopy 2008; 40: 1008-1015
• 30 Orman ES, Kim HP, Bulsiewicz WJ et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett’s esophagus with radiofrequency ablation. Am J Gastroenterol 2013; 108: 187-195
• 31 Vaccaro BJ, Gonzalez S, Poneros JM et al. Detection of intestinal metaplasia after successful eradication of Barrett’s esophagus with radiofrequency ablation. Dig Dis Sci 2011; 56: 1996-2000
• 32 Krishnan K, Pandolfino JE, Kahrilas PJ et al. Increased risk for persistent intestinal metaplasia in patients with Barrett’s esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology 2012; 143: 576-581
• 33 Gray NA, Odze RD, Spechler SJ. Buried Metaplasia after endoscopic ablation of Barrett’s esophagus: a systematic review. Am J Gastroenterol 2011; 106: 1899-1908
• 34 Titi M, Overhiser A, Ulusarac O et al. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett’s esophagus. gastroenterology 2012; 143: 564-566
• 35 Lee JK, Cameron RG, Binmoeller KF et al. Recurrence of subsquamous dysplasia and carcinoma after successful endoscopic and radiofrequency ablation therapy for dysplastic Barrett’s esophagus. Endoscopy 2013; 45: 571-574
• 36 Bennett C, Vakil N, Bergman J et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012; 143: 336-346